NovoCure aims for $344M IPO; NPR takes on Bayer's Essure;

@FierceMedDev: ICYMI: Upstart Establishment gets $20M+ to bring safer breast implants with nanotech, RFID tracking to U.S. Article | Follow @FierceMedDev

@StacyALawrence: ICYMI last week: Google hires top government brain scientist to probe mental illness. Story | Follow @StacyALawrence

@EmilyWFierce: Some light reading on Otsuka and Proteus' antipsychotic with a built-in sensor. Wired story | Follow @EmilyWFierce

> The first medical device IPO of the fall for Penumbra ($PEN) got a hefty 38% first day trading bounce on Friday. Now another highly anticipated company, NovoCure, has set terms for an IPO it expects will raise $189 million for the company and $344 million in total. It will sell 7.5 million shares at a range of $26 to $29 per share, with an additional 5 million sold by existing shareholders. The overallotment will consist of another 1.875 million shares from investors. More

> NPR covered the complaints against contraceptive device Essure from Bayer ahead of the Sept. 24 FDA meeting slated to review it. Article

> Cardiosolutions' Mitra-Spacer System has had its first-in-human implants; it is intended to treat or bridge heart failure patients whose operative mortality risk for undergoing conventional open-heart surgery is deemed too high. More

Biotech News

@FierceBiotech: COMMENTARY: Why would Martin Shkreli hike an old drug price by 5000%? Only a 'moron' would ask. More | Follow @FierceBiotech

@JohnCFierce: One win, one loss in Merck's PhIII double header for C diff. Story | Follow @JohnCFierce

@DamianFierce: Filed under Roche Hubris Watch: Reuters article | Follow @DamianFierce

> In Addyi's shadow, Richter walks away from a female libido drug. Report

> Gilead's new pangenotype hep C combo scores stellar results in PhIII. Story

> UniQure beats a path to Phase III after a 'promising' gene therapy trial. Article

Pharma News

@FiercePharma: Consumer ranking of fast-food chains' antibiotics in meat calls out FDA, industry for change. FierceAnimalHealth report | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Ireland pharma biz going to the dogs, so to speak. Nextvet picks up biologics plant there. Item | Follow @EricPFierce

@CarlyHFierce: Watch out, Afinitor. Bristol's 'breakthrough' Opdivo is coming for you. More from FiercePharmaMarketing | Follow @CarlyHFierce

> Hillary Clinton to lay out her plan for cutting drug prices. Article

> Bloomberg: Sanofi, Pfizer mull potential deal for Mexican generics maker Rimsa. More

Animal Health News

> Science think tank calls for global phaseout of antibiotics in agriculture. More

> Merck pioneers injectable vaccine for common pig disease. Item

> VetStem launches trial of drug-free method for preventing hemorrhage in horses. Story

> Consumer ranking of fast-food chains' antibiotics in meat calls out FDA, industry for change. Article

> ViroVet spins out of Aratana with focus on livestock health. Report

Biotech IT News

> Traders pay SEC $30M to settle newswire hacking case. More

> Google lures NIH mental health chief to life sciences team. News

> Harvard connection helps WuXi NextCODE land Chinese hospital contract. Report

> Microsoft lands cloud genomics infrastructure deal with UC Santa Cruz. Article

> Number of clinical trials to use wearables nears 300. Story

Pharma Marketing News

> More followers and more daily tweeting as Big Pharma's Twitter presence grows. Story

> Sanofi, Pfizer said to be among suitors for Mexico's Rimsa. Item

> Janssen's latest Prezcobix effort taps HIV activists to curate patient-story contest. More

> For sale: Orange paint. It might just become your brand's signature. Editor's Corner

> Watch out, Afinitor. Bristol's 'breakthrough' Opdivo is coming for you. Article

Suggested Articles

BD will begin offering a point-of-care COVID-19 antibody assay, which operates like a combination of a blood glucose test and a home pregnancy test.

Smith+Nephew is contracting with the U.K. government to build a new ventilator specifically designed for large-scale production.

NantWorks’ ImmunityBio has begun a supercomputing collaboration with Microsoft to map out the spike protein of the novel coronavirus.